利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.016 秒)

    Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
    2.
    发明授权
    Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha 有权
    抑制环氧合酶-2和肿瘤坏死因子α的方法

    公开(公告)号：US06319910B1

    公开(公告)日：2001-11-20

    申请号：US09213149

    申请日：1998-12-17

    申请人： Ashok Amin ,  Steven Abramson ,  Inoravadan V. Patel

    发明人： Ashok Amin ,  Steven Abramson ,  Inoravadan V. Patel

    IPC分类号： A61K3165

    CPC分类号： A61K31/65 ,  Y02A50/411

    摘要： Chemically modified tetracyclines are a new class of non-steroidal anti-inflammatory drugs which inhibit cyclooxygenase-2 and tumor necrosis factor alpha. These chemically modified tetracyclines are used in a method for inhibiting COX-2, which in turn inhibits PGE2, and/or inhibiting TNF&agr;. They are also used in a method for treating a disease or disorder associated with elevated activities of COX-2 (i.e., increased production of PGE2) and/or TNF&agr;.

    摘要翻译： 化学修饰的四环素是抑制环氧合酶-2和肿瘤坏死因子α的新一类非甾体抗炎药物。 这些化学修饰的四环素用于抑制COX-2的方法，COX-2又抑制PGE2和/或抑制TNFα。 它们还用于治疗与COX-2活性升高相关的疾病或病症（即增加PGE2的产生）和/或TNFα的方法。

    Treatment for reactive arthritis or bursitis
    4.
    发明授权
    Treatment for reactive arthritis or bursitis 失效
    治疗反应性关节炎或滑囊炎

    公开(公告)号：US06765000B2

    公开(公告)日：2004-07-20

    申请号：US10271117

    申请日：2002-10-15

    申请人： Ernest L. Bonner, Jr. ,  Robert Hines

    发明人： Ernest L. Bonner, Jr. ,  Robert Hines

    IPC分类号： A61K3165

    CPC分类号： A61K31/522 ,  A61K31/198 ,  A61K31/4164 ,  A61K31/4406 ,  A61K31/65 ,  A61K2300/00

    摘要： A treatment for conditions in human beings associated with either or both reactive arthritis or bursitis comprising a combination of acyclovir, minocycline hydrochloride, and metronidazole. An alternate treatment comprises the combination of valacyclovir hydrochloride, minocycline hydrochloride, and metronidazole.

    摘要翻译： 与任何一种或两种反应性关节炎或滑囊炎相关的人类状况的治疗包括阿昔洛韦，米诺环素盐酸盐和甲硝唑的组合。 替代治疗包括盐酸伐昔洛韦，盐酸米诺环素和甲硝唑的组合。

    Method of inhibiting membrane-type matrix metalloproteinase
    7.
    发明授权
    Method of inhibiting membrane-type matrix metalloproteinase 失效
    抑制膜型基质金属蛋白酶的方法

    公开(公告)号：US06277061B1

    公开(公告)日：2001-08-21

    申请号：US09052222

    申请日：1998-03-31

    申请人： Lorne M. Golub ,  Hsi-Ming Lee ,  Timo Sorsa ,  Olli Teronen ,  Tuula Salo

    发明人： Lorne M. Golub ,  Hsi-Ming Lee ,  Timo Sorsa ,  Olli Teronen ,  Tuula Salo

    IPC分类号： A61K3165

    CPC分类号： A61K31/65

    摘要： The invention is a method of inhibiting the activity of membrane-type matrix metalloproteinase (MT-MMP) in biological systems. Accordingly, the invention permits the treatment of medical conditions in mammals that are characterized by MT-MMP activity, and especially those conditions characterized by excessive MT-MMP activity. The method employs a tetracycline compound, preferably a non-antimicrobial tetracycline, and more preferably 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3) or 6-&agr;-deoxy-5-hydroxy-4-de(dimethylamino)tetracycline (CMT-8) to inhibit the MT-MMP activity.

    摘要翻译： 本发明是抑制生物系统中膜型基质金属蛋白酶（MT-MMP）活性的方法。 因此，本发明允许治疗以MT-MMP活性为特征的哺乳动物中的医学病症，特别是以过量MT-MMP活性为特征的那些病症。 该方法采用四环素化合物，优选非抗微生物四环素，更优选6-去甲基-6-脱氧-4-脱（二甲基氨基）四环素（CMT-3）或6-α-脱氧-5-羟基-4- de（二甲基氨基）四环素（CMT-8）抑制MT-MMP活性。

    Reducing tetracycline resistance in living cells
    9.
    发明授权
    Reducing tetracycline resistance in living cells 失效

    公开(公告)号：US06756365B2

    公开(公告)日：2004-06-29

    申请号：US09504697

    申请日：2000-02-16

    申请人： Stuart B. Levy

    发明人： Stuart B. Levy

    IPC分类号： A61K3165

    CPC分类号： C07D295/13 ,  A61K31/65 ,  C07C237/26 ,  C07C323/29 ,  C07C2601/08 ,  A61K2300/00

    摘要： The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.